RxDoctor Payments Data

Malorie Mann, APRN

Family · Bowling Green, KYNPI 1417601444

Payments from drug & device makers

$2,318in general payments, 2019–2025

Across 74 payments — averaging $31.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$932
  • AbbVie$619
  • Alkermes, Inc.$223
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$160
  • Indivior Inc.$113
  • GSK$52
  • plus $218 from 10 others

What the payments were for

  • Food & beverage$2,30399%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,318 in reported general payments places this provider in the 80th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$6,330
Medicare patients
42
Services billed
121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin24$30,505
Trelegy ElliptaFluticasone/Umeclidin/Vilanter21$18,081
OzempicSemaglutide16$17,146
EliquisApixaban13$7,697
SynthroidLevothyroxine Sodium14$861
Ventolin HfaAlbuterol Sulfate13$728
Buspirone Hcl42$721
Albuterol Sulfate HfaAlbuterol Sulfate27$658
Atorvastatin Calcium113$607
Desvenlafaxine Succinate ErDesvenlafaxine Succinate20$585
Levothyroxine Sodium59$568
Metoprolol Succinate75$548
Bupropion XlBupropion Hcl37$533
Levocetirizine Dihydrochloride14$495
Famotidine61$482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$52$18,08121 claims
Novo NordiskOzempic$13$17,14616 claims
PfizerEliquis$34$7,69713 claims
AbbVieSynthroid$619$86114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 4,374 family providers in Kentucky.

Other family in Bowling Green

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →